Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

KYTX

Kyverna Therapeutics Inc.

Jun 14 • 04:00PM ET

9.53

Dollar change -4.91
Percentage change -34.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF SCHA VTI SCHB FHLC IBRN BMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	55.43%	Shs Outstand	43.12M	Perf Week	-27.42%
Market Cap	410.93M	Forward P/E	-	EPS next Y	-4.12	Insider Trans	9.45%	Shs Float	19.21M	Perf Month	-39.95%
Income	-	PEG	-	EPS next Q	-0.74	Inst Own	38.56%	Short Float	15.22%	Perf Quarter	-67.92%
Sales	-	P/S	-	EPS this Y	96.08%	Inst Trans	-	Short Ratio	6.51	Perf Half Y	-
Book/sh	8.37	P/B	1.14	EPS next Y	-17.45%	ROA	-	Short Interest	2.92M	Perf Year	-
Cash/sh	8.58	P/C	1.11	EPS next 5Y	-	ROE	-	52W Range	11.75 - 35.06	Perf YTD	-68.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-72.82%	Beta	-
Dividend TTM	-	Quick Ratio	17.17	Sales past 5Y	-37.90%	Gross Margin	-	52W Low	-18.89%	ATR (14)	1.82
Dividend Ex-Date	-	Current Ratio	17.17	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	31.75	Volatility	21.96% 13.55%
Employees	96	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	42.75
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-	Payout	-	Rel Volume	9.59	Prev Close	14.44
Sales Surprise	-	EPS Surprise	-33.33%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	448.90K	Price	9.53
SMA20	-29.50%	SMA50	-41.66%	SMA200	-54.93%	Trades		Volume	4,304,557	Change	-34.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
02:59PM	Loading…
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walker Karen Marie	Chief Technology Officer	Jun 06 '24	Option Exercise	4.42	9,636	42,591	9,636	Jun 10 06:56 PM
Jones Ryan Alexander	Chief Financial Officer	May 28 '24	Option Exercise	0.73	18,016	13,152	43,950	May 29 04:33 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
Northpond Ventures III GP, LLC	Former 10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	450,000	Feb 12 05:51 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	3,163,868	Feb 14 05:26 PM
Vida Ventures, LLC	10% Owner	Feb 12 '24	Buy	22.00	253,136	5,568,992	252,553	Feb 14 07:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYTX

Kyverna Therapeutics Inc.

Upgrade your FINVIZ experience